Oral administration of a zinc complex improves type 2 diabetes and metabolic syndromes

Biochemical and Biophysical Research Communications

Volumn 351, Issue 1, 2006, Pages 165-170

  Adachi, Yusuke ^a   Yoshida, Jiro ^b   Kodera, Yukihiro ^b   Kiss, Tamas ^c   Jakusch, Tamas ^c   Enyedy, Eva A ^c   Yoshikawa, Yutaka ^a   Sakurai, Hiromu ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b WAKUNAGA PHARMACEUTICAL CO LTD   (Japan)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Adiponectin; Hypertension; Insulin resistance; Leptin resistance; Metabolic syndromes; Obesity linked type 2 diabetes; Zn(II) complex

Indexed keywords

ADIPONECTIN; UNCLASSIFIED DRUG; ZINC ALLIXIN COMPLEX; ZINC COMPLEX; ZINC THIOLIXIN N METHYL COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG EFFECT; DRUG HALF LIFE; DRUG TISSUE LEVEL; DRUG UPTAKE; GASTROINTESTINAL ABSORPTION; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; HYPERLEPTINEMIA; HYPERTENSION; INSULIN LIKE ACTIVITY; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, TYPE 2; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; TREATMENT OUTCOME; ZINC;

ALLIUM SATIVUM;

EID: 33750292900     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.10.014     Document Type: Article

References (29)

1. Amos A.F., McCarty D.J., and Zimmet P. The rising global burden of diabetes and its complications: estimates and projections by 2010. Diabet. Med. 14 (1997) S5-S85
2. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414 (2001) 821-827
3. Underwood E.J. In Trace Elements in Human and Animal Nutrition. fourth ed. (1977), Academic Press, New York pp. 230-245
4. Chen M.D., Liou S.J., Lin P.Y., Yang V.C., Alexander P.S., and Lin W.H. Effects of zinc supplementation on the plasma glucose level and insulin activity in genetically obese (ob/ob) mice. Biol. Trace Elem. Res. 61 (1998) 303-311
5. Simon S.F., and Taylor C.G. Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exp. Biol. Med. 226 (2001) 43-51
6. Shisheva A., Gefel D., and Shechter Y. Insulin-like effects of zinc ion in vitro and in vivo. Diabetes 41 (1992) 982-988
7. Sakurai H., Kojima Y., Yoshikawa Y., Kawabe K., and Yasui H. Antidiabetic vanadium(IV) and zinc(II) complexes. Coord. Chem. Rev. 226 (2002) 187-198
8. Kojima Y., Yoshikawa Y., Ueda E., Kondo M., Takahashi S., Matsukura T., Sakurai H., Hiori T., Imaoka S., and Funae Y. Blood glucose lowering and toxicological effects of zinc(II) complexes with maltol, threonine, and picolinic acid. Res. Commun. Mol. Pathol. Pharmacol. 112 (2002) 91-104
9. Iwatsuka H., Shino A., and Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol. Jpn. 17 (1970) 23-35
10. Taketomi S., Ishikawa E., and Iwatsuka H. Lipogenic enzymes in two types of genetically obese animals, fatty rats and yellow KK mice. Horm. Metab. Res. 7 (1975) 242-246
11. 4) coordination mode. Chem. Lett. 8 (2000) 874-875
12. y mice with type 2 diabetes mellitus. Biochem. Biophys. Res. Commun. 281 (2001) 1190-1193
13. Adachi Y., Yoshida J., Kodera Y., Kato A., Yoshikawa Y., Kojima Y., and Sakurai H. A new insulin-mimetic bis(allixinato)zinc(II) complex: structure-activity relationship of zinc(II) complexes. J. Biol. Inorg. Chem. 9 (2004) 885-893
14. Adachi Y., Yoshikawa Y., Yoshida J., Kodera Y., Katoh A., Kojima Y., and Sakurai H. Zinc complexes with allixin-derivatives as oral therapeutics for type 2 diabetes. Biomed. Res. Trace Elem. 17 (2006) 17-24
15. 2) coordination mode: bis(1,6-dimethyl-3-hydroxy-5-methoxy-2-pentyl-1,4-dihydropyridine-4- dithionato)zinc(II). Chem. Lett. 34 (2005) 656-657
16. Mager H., and Goller G. Resampling methods in sparse sampling situations in preclinical pharmacokinetic studies. J. Pharm. Sci. 87 (1998) 372-378
17. Matsuzawa Y., Funahashi T., and Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann. N.Y. Acad. Sci. 892 (1999) 146-154
18. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett. 580 (2006) 2917-2921
19. Ceddia R.B., Koistinen H.A., Zierath J.R., and Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J. 16 (2002) 1163-1176
20. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., and Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116 (2006) 1784-1792
21. Matsuzawa Y., Funahashi T., Kihara S., and Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 29-33
22. 4) coordination mode. Chem. Lett. 34 (2005) 1694-1695
23. Aizawa-abe M., Ogawa Y., Masuzaki H., Ebihara K., Satoh N., Iwai H., Matsuoka N., Hayashi T., Hosoda K., Inoue G., Yoshimasa Y., and Nakao K. Pathophysiological role of leptin in obesity-related hypertension. J. Clin. Invest. 105 (2000) 1243-1252
24. Ohashi K., Kihara S., Ouchi N., Kumada M., Fujita K., Hiuge A., Hibuse T., Ryo M., Nishizawa H., Maeda N., Maeda K., Shibata R., Walsh K., Funahashi T., and Shimomura I. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 47 (2006) 1108-1116
25. Levine A.S., McClain C.J., Handwerger B.S., Brown D.M., and Morley J.E. Tissue zinc status of genetically diabetic and streptozotocin-induced diabetic mice. Am. J. Clin. Nutr. 37 (1983) 382-386
26. Kechrid Z., and Bouzerna N. Effect of zinc deficiency on zinc and carbohydrate metabolism in genetically diabetic (C57BL/Ksj db+/db+) and non-diabetic original strain (C57BL/Ksj) mice. Turk. J. Med. Sci. 34 (2004) 367-373
27. Salgueiro M.J., Krebs N., Zubillaga M.B., Weill R., Pastaire E., Lysionek A.E., Caro R.A., Paoli T.D., Hager A., and Boccio J. Zinc and diabetes mellitus: is there a need of zinc supplementation in diabetes mellitus patients?. Biol. Trace Elem. Res. 81 (2001) 215-228
28. Kinlaw W.B., Levine A.S., Morley J.E., Silvis S.E., and McClain C.J. Abnormal zinc metabolism in type II diabetes mellitus. Am. J. Med. (1983) 273-277
29. Quraishi I., Collins S., Pestaner J.P., Harris T., and Bagasra O. Role of zinc and zinc transporters in the molecular pathogenesis of diabetes mellitus. Med. Hypotheses 65 (2005) 887-892